Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization

@article{SnchezOrtega2015PlerixaforIP,
  title={Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization},
  author={Isabel S{\'a}nchez-Ortega and Sergio Querol and Maite Encuentra and Sandra Ortega and Assumpta Serra and Jorge S{\'a}nchez-Villegas and Joan Ram{\'o}n Grifols and M M Pujol-Balaguer and M Pujol-Bosch and Josep Mar{\'i}a Mart{\'i} and Tom{\'a}s Garc{\'i}a-Cerecedo and Pere Barba and J. M. Sancho and Albert Esquirol and J Gilbert Sierra and R. Duarte},
  journal={Bone Marrow Transplantation},
  year={2015},
  volume={50},
  pages={34-39}
}
This retrospective study presents data from 105 consecutive multiple myeloma and lymphoma patients who had PB CD34+ cell counts <10/μL on day 4 of steady-state G-CSF mobilization for autologous hematopoietic cell transplantation. Our results confirm the capacity of plerixafor to improve mobilization outcomes in this clinical setting. In addition, they show… CONTINUE READING